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Monoclonal antibodies are the leading class of biopharmaceuticals in terms of
numbers approved for therapeutic purposes. Antigen‐binding fragments (Fab) are
also used as biotherapeutics and used widely in research applications. The dominant
expression systems for full‐length antibodies are mammalian cell‐based, whereas for
Fab molecules the preference has been an expression in bacterial systems. However,
advances in CHO and downstream technologies make mammalian systems an
equally viable option for small‐ and large‐scale Fab production. Using a panel of
full‐length IgG antibodies and their corresponding Fab pair with different antigen
specificities, we investigated the impact of the IgG and Fab molecule format on
production from Chinese hamster ovary (CHO) cells and assessed the cellular
capability to process and produce these formats. The full‐length antibody format
resulted in the recovery of fewer mini‐pools posttransfection when compared to the
corresponding Fab fragment format that could be interpreted as indicative of a
greater overall burden on cells. Antibody‐producing cell pools that did recover were
subsequently able to achieve higher volumetric protein yields (mg/L) and specific
productivity than the corresponding Fab pools. Importantly, when the actual mole-
cules produced per cell of a given format was considered (as opposed to mass), CHO
cells produced a greater number of Fab molecules per cell than obtained with the
corresponding IgG, suggesting that cells were more efficient at making the smaller
Fab molecule. Analysis of cell pools showed that gene copy number was not cor-
related to the subsequent protein production. The amount of mRNA correlated with
secreted Fab production but not IgG, whereby posttranscriptional processes act to
limit antibody production. In summary, we provide the first comparative description
of how full‐length IgG and Fab antibody formats impact on the outcomes of a cell
line construction process and identify potential limitations in their production that
could be targeted for engineering increases in the efficiency in the manufacture of
these recombinant antibody formats.
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1 | INTRODUCTION
Monoclonal antibodies and immunoglobulins are an important and
prevalent class of biopharmaceuticals with many approved for ther-
apeutic use or in development (Akram et al., 2021; O'flaherty
et al., 2020; Walsh, 2018). Between 2014 and 2019, the total number
of FDA‐approved biopharmaceuticals was 129, out of which 66
(51%) were monoclonal antibodies or conjugates (O'flaherty
et al. 2020). Engineering of recombinant proteins alongside biopro-
cess and host cell improvements has enabled antibody production
processes to produce >10 g/L yields in CHO cell cultures (Huang
et al., 2010). In addition, truncated forms of full‐length antibodies
including antigen‐binding fragments (Fab) have also been used in
therapeutic applications (reviewed in Sandomenico et al. [2020]).
Examples of approved Fab fragments include Certolizumab pegol
(CIMZIA®), developed and manufactured by UCB Pharma; a PEGy-
lated Fab fragment from a humanized anti‐TNF‐α monoclonal anti-
body for the treatment of rheumatoid arthritis. Ranibizumab
(Lucentis®), a humanized Fab fragment, has been approved for the
treatment of angiogenesis and macular edema (Sandomenico
et al., 2020). The Fab antibody fragment Idarucizumab (Praxbind®)
has also been approved for neutralization of the anticoagulant effect
of dabigatran (Walsh, 2018). Applications of this alternative to full‐
length antibodies continue to grow alongside the development of
other antibody fragment‐inspired formats including bi‐specific
and tri‐specific antibodies offering different modes of action
(Spiess et al., 2015).
For the production of antibodies and antibody‐based format
molecules, a range of different expression systems has been used.
Mammalian expression systems, in particular, Chinese hamster ovary
(CHO) cells are the prevalent host for recombinant protein produc-
tion due to their ability to perform the complex posttranslational
modifications required (Walsh, 2018). In contrast, Escherichia coli
(E. coli) is a preferred expression host for Fab molecules due to the
simplicity of the process compared to mammalian cells and reduced
time‐scales to manufacture Fab yields at gram/liter scale (Gupta &
Shukla, 2017). However, challenges with bacterial cells include in-
clusion body formation, high endotoxin levels and, importantly for
antibodies, the lack of correct posttranslational processing and
modifications, in particular N‐linked glycosylation. There is a large
amount of literature describing the expression of Fab fragments and/
or full‐length antibodies in bacterial cells (e.g., Dariushnejad
et al., 2019; Ellis et al., 2017; Farajnia et al., 2020; Gadkar et al., 2015;
Gundinger & Spadiut, 2020; Humphreys et al., 1996; 2007; Kumar
et al., 2019; Rodríguez‐Carmona et al., 2012; Shatz et al., 2019;
Yusakul et al., 2018) or alternative system such as insect and yeast
expressions system (e.g., Joosten et al., 2003; Mizote et al., 2020;
Nakamura et al., 2020). In comparison, there are limited examples
describing Fab fragment expression in mammalian cells, where yields
of up to 4 g/L have been reported (Camper et al., 2011; Lebozec
et al., 2018, Samuelsson et al., 1996; Schatz et al., 2003; Takagi
et al., 2017; Tang et al., 2018; Vazquez‐Lombardi et al., 2018).
Surprisingly, few studies have compared the production of full‐length
antibodies and their corresponding Fab molecules in bacterial and/or
mammalian cells.
Here, we describe the production of full‐length humanized IgG
antibodies and antibody‐derived Fab molecules using a proprietary
CHO cell expression system. A panel of full‐length IgG1 and partner
Fab constructs were designed with the same variable domain se-
quences or antigen specificity. We then compared how the IgG1 and
Fab formats impacted the cell line construction process, recovery of
mini‐pools, and protein expression through a standard cell line con-
struction process. The results of the subsequent analyses are
described.
2 | MATERIALS AND METHODS
2.1 | Cell lines and DNA constructs
Suspension CHO‐DG44 cells were grown in commercial DG44
medium (LifeTechnologies). Separate heavy chain (HC) and light chain
(LC) genes were cloned into a proprietary vector using standard
cloning methods. All HC and LC DNA sequences were commercially
synthesized by ATUM and the codon usage was consistent across
both IgG and Fab sequences. The plasmid vector topology was such
that each individual recombinant gene (HC/LC) for the Fab or IgG1
was driven by a separate promoter of the same type. For the full‐
length antibodies, HCs contained the same human IgG1 CH1, CH2,
and CH3 domain, and the same human kappa LC but with VH and VL
domains with different antigen specificity termed A, B, and C. Fab
molecules contained the same HC CH1 and LC CL domain withVH and
VL domains with the corresponding antigen specificity. The number
of amino acids in the IgG1 and Fab HC and LC were within the normal
range for these formats. Six molecules in total were generated for
analysis, IgG1 A, IgG1 B, IgG1 C, Fab A, Fab B, and Fab C.
2.2 | Stable cell mini‐pool generation
Stable CHO cell pools were generated by transfecting linear DNA,
encoding the IgG1 and Fab molecules, into suspension CHO‐DG44
cells using the Cell Line Nucleofector™ V Kit (Lonza) according to
manufacturer's instructions. 1 × 107 cells and 100 µg linearized DNA
were used per T‐75 flask. 1 × 107 viable CHO‐DG44 cells were har-
vested and centrifuged (190×g, 5 min). The supernatant was dis-
carded and cells gently re‐suspended in 1ml nucleofector solution
and the appropriate volume of DNA was added and mixed. An equal
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volume of the DNA and cell suspension was transferred into 10
cuvettes. Each cuvette was electroporated (in a Nucleofector® I de-
vice) and nonselective CD‐DG44 medium (supplemented with glu-
tamine and Pluronic acid) was added. After electroporation and media
addition, the contents of all ten cuvettes were transferred into a
T‐flask containing pre‐warmed nonselective media. The T‐flask was
incubated at 36.8°C, 7.5% CO2 in a static incubator for 24 h. In total,
two T‐75 flasks were prepared per transfection.
At 24 h posttransfection, cells were counted and centrifuged at
900×g, 5 min. After centrifugation, the supernatant was discarded
and cells re‐suspended into selective CD‐CHO media (supplemented
with glutamine and methotrexate [MTX]) and plated out into 96‐well
plates. For every transfection, twenty 96‐well plates were plated out
with 4000 cells seeded per well. The 96‐well plates were incubated
at 36.8°C, 7.5% CO2 in a static incubator for approximately 14 days.
Single colonies (termed a mini‐pool) in the 96‐well plates were
identified using the CloneSelect Imager (Molecular Devices) and
transferred into wells of a 24‐well plate (one colony per well). For
each transfection, up to a maximum of 96 colonies were transferred.
The resulting mini‐pools were grown in selective CD‐CHO media
(supplemented with glutamine and MTX) for 10 days until cells were
confluent. After 10 days, 200 µl of culture supernatant was sampled
per well to determine the product titer and confirm expression of the
molecule of interest using the Octet® QK with Protein G biosensors
(FortéBio).
The top‐20 ranking mini‐pools by titer were transferred into
T‐25 flasks in selective CD‐CHO media (supplemented with gluta-
mine and MTX) for 7 days. Subsequently, all T‐25 flasks were
transferred into 125ml Erlenmeyer shake flasks in HyClone ActiSM™
medium (supplemented with glutamine and MTX) and incubated in a
humidified shaking incubator at 36.8°C, 7.5% CO2, and 198 rpm.
Mini‐pools were cultured in shake flasks until the culture viability
recovered (>90%). For the top‐20 mini‐pools, a 10‐day batch
overgrow culture was then performed. After 10 days, the product
titer in the culture medium was determined using Protein G High‐
Performance Liquid Chromatography (HPLC). The top‐12 ranking
mini‐pools by titer were selected for further study and
cryopreserved.
2.3 | High‐performance liquid
chromatography analysis
After a 10‐day batch overgrow culture, culture supernatants were
harvested from each shake flask by centrifugation (5000×g, 20min).
Before analysis, the supernatants were filtered using Steriflip‐GP
sterile centrifuge tube filter units (Millipore). A 300 µl aliquot of the
filtered supernatant was transferred into a Chromacol fixed insert glass
vial (Thermo Fisher Scientific) and analyzed on an Agilent Technologies
1200 series HPLC system, using a Protein G column and the Agilent
Chemstation (Rev.B.04.03(16)) software was used for analysis.
2.4 | Batch culture analysis of the highest
expressing mini‐pools
200ml cultures in 1 L shake flasks were set up for the top‐12 mini‐
pools for each molecule of interest for a 9‐day batch overgrow culture.





(HPLC) DNA (qPCR) RNA (qPCR)
Protein (Western
blot analysis)
Day 0: Cultures were seeded at 0.2 × 106 cells/ml in 200ml total volume
Day 1: x
Day 2: x
Day 3: x x x x x
Day 4: x
Day 5: x
Day 6: x x x x x
Day 7: x
Day 8: x
Day 9: x x x x x
Sample
details:
0.6 ml/sample 2ml culture
medium/sample
5 × 106 cells/
sample
5 × 106 cells/
sample
1 × 107 cells/
sample and
culture medium
Note: The “X” symbol marks each day a sample was taken for cell counting, titer measurements, DNA, RNA, and protein analysis. In addition, the culture
volume or number of viable cells sampled are detailed.
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Cell counts were taken every day using a Vi‐CELL automated cell
counter (Beckman Coulter). Cultures were sampled for culture medium
and cell pellets on specific days (detailed in Table 1) for titer mea-
surements (product concentration), DNA, RNA, and protein analyses.
Triplicate samples were taken at the appropriate time points.
2.5 | Preparation of intracellular and secreted
protein samples
From batch cell cultures, 1 × 107 viable cells were harvested by cen-
trifugation (5000×g, 10min) and the culture supernatant isolated. The cell
pellet was lysed directly in radio‐immunoprecipitation assay (RIPA) buffer
(125mM sodium chloride, 10mM sodium fluoride, 1% (v/v) Triton‐X,
0.2% (w/v) SDS, 10mM sodium pyrophosphate, 0.5% (w/v) sodium
deoxycholate, 25mM HEPES, and 10mM sodium orthovanadate) sup-
plemented with protease inhibitor cocktail (cat no. P8340, Sigma‐Aldrich)
and passed through a syringe and 21‐gauge needle. The lysate was then
incubated on ice for 15min. An aliquot of the lysate was mixed in equal
volumes with 2× sample buffer (20% (v/v) glycerol, 125mM Tris–HCl,
4% (w/v) SDS, and 0.01% (v/v) bromophenol blue) before Western blot
analysis. For secreted protein analysis, an aliquot of the culture super-
natant was mixed in equal volumes with a 2× sample buffer.
2.6 | SDS‐PAGE and Western blot analysis
Proteins were resolved via SDS‐PAGE and transferred onto ni-
trocellulose membrane as detailed previously (Hussain et al., 2018).
Membranes were blocked in 5% (w/v) milk in phosphate‐buffered
saline (PBS; 137mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 2mM
KH2PO4, and pH 7.4) with 0.1% (v/v) Tween‐20 (5% mPBS‐T) for 1 h
at room temperature before incubation with primary antibodies in 5%
mPBS‐T solution for 1 h at room temperature. Primary antibodies
used include anti‐human CH1 domain antibody (generated in‐house
by UCB), anti‐human kappa antibody (1:1000, cat no. 9230‐01,
Southern Biotech), and anti‐ERK2 (1:1000, cat no. sc‐81459, Santa
Cruz Biotechnology) as an intracellular sample loading control. Blots
were incubated with a suitable IRDye® 800CW secondary antibody
(1:15000, LI‐COR Biosciences) in 5% mPBS‐T solution for 1 h at room
temperature. The membrane was washed three times for 5 min each
with 0.1% (v/v) PBS‐T after each antibody incubation. Proteins were
detected using Bio‐Rad ChemiDoc MP imaging system according to
the manufacturer's instructions. Quantification of bands was com-
pleted using the Bio‐Rad Image Lab™ software (Version 6.0.1).
All graphs were prepared and statistical analysis was performed in
GraphPad Prism (Version 8.4.0).
2.7 | RNA extraction
Total RNA was extracted from frozen pellets using the mirVana™
miRNA Isolation Kit with phenol and eluted in DNase‐free water.
The eluted RNA was concentrated and on‐column DNase treated
using RNA Clean & Concentrator™‐25 with Zymo‐Spin™ IIC Columns
(Zymo Research) and DNase I Set with DNA Digestion Buffer (Zymo
Research). After assessing for the presence of contaminating genomic
DNA (gDNA) by reverse transcription‐quantitative polymerase chain
reaction (RT‐qPCR), a fraction of the total RNA volume was further
treated withThermo Scientific™ RapidOut DNA Removal Kit (Thermo
Fisher Scientific). This RNA, free of gDNA contamination, was used
for all subsequent RT‐qPCR. RNA quality was checked at each step
using a NanoDrop instrument.
2.8 | Reverse transcription‐quantitative
polymerase chain reaction
Power SYBR® Green RNA‐to‐CT™ 1‐Step Kit (Thermo Fisher Scien-
tific) was used following the manufacturer's instructions. 80 ng of
RNA was used for each reaction. Transcript numbers were quantified
using a standard curve.
2.9 | Genomic DNA extraction
Genomic DNA was extracted from frozen pellets using the PureLink®
Genomic DNA Kit (Invitrogen), following the manufacturer's in-
structions. 25 ng of gDNA was used for qPCR analysis using the
QuantiFast SYBR Green PCR Kit (Qiagen). Copy number was quan-
tified using a plasmid standard curve and subsequently calculated
per cell.
3 | RESULTS AND DISCUSSION
3.1 | Generation of CHO cell pools expressing
full‐length IgGs show a lower recovery
posttransfection compared to those expressing the
Fab fragment format
A panel of three IgG1 and Fab formats (with the same variable do-
main/antigen specificity) were expressed side‐by‐side in the pro-
prietary CHO cell expression system. The impact of the different
molecule formats (with the same antigen‐binding targeting) on cell
pool recovery posttransfection including the number of colonies that
emerge posttransfection, cell growth, and protein expression of co-
lonies as they were expanded through a standard cell line construc-
tion process was then assessed. In addition, we performed a
molecular characterization of the industrially standard cell lines
generated to assess the capability of cells to process and produce
IgG1 or Fab formats and identify potential limitations in the pro-
duction of such molecules.
For the comparisons, we generated three pairs of molecules that
shared the same antigen specificity or variable domain but were ei-
ther in a Fab or IgG1 format giving a total of six molecules. The three
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antigen specificities were termed A, B, and C (Section 2.1) and did not
target any CHO host cell proteins. In each Fab format, a heavy
VH–CH1 polypeptide chain was covalently paired with a separate
Kappa VL–CL polypeptide chain (~50 kDa), whereas the IgG1 contains
two full‐length HCs and two Kappa LCs to form a full‐length antibody
structure (~150 kDa; Feige et al., 2010; Huber et al., 1976). The Fab
domains did not contain a free C‐terminal cysteine residue (no
hinge Fab; Dave et al., 2016). A further molecular distinction between
the molecules was the presence of an N‐glycosylation site within the
Fc region of the IgG1 format which was absent in the Fab format.
No theoretical N‐glycan sites were present within the different
variable regions.
Vectors were generated for each molecule and following line-
arisation were stably transfected into CHO cells, a summary of the
process is depicted in Figure 1a. Following transfection, cells were
plated into 96‐well plates as pools and allowed to recover for
2–3 weeks (Section 2.2). At that stage, the 96‐well plates were
analyzed for the presence of presumed single colonies (here termed
“mini‐pools”). The percentage number of wells containing mini‐pools
out of the total number of wells seeded (at the 96‐well plate stage)
was greater for the Fab format (5%–14%) than for the IgG format
(2%–4%), however, the difference was not statistically significant
(p = 0.0970; Figure 1b). Within the general recovery banding ob-
served for each format, differences were observed in the recovery
depending on the variable domain sequence.
The greater percentage recovery of the Fab format offered the
potential to expand a greater number of mini‐pools through to the
24‐well stage. Consequently, this allowed for the selection of
96 mini‐pools to expand from the Fab formats whereas the expan-
sion of mini‐pools from the IgG1 formats was limited due to fewer
wells recovering (Figure 1c). Indeed, all (<96) mini‐pools that re-
covered were taken through from each of the IgG1 transfections.
Once mini‐pools were at a sufficient cell concentration in 24‐well
plates they were subjected to a 9‐day batch overgrow after which
the product concentration in the culture medium was measured by
Octet® (Protein G) to determine the proportion of mini‐pools that
gave a detectable protein concentration (Figure 1d). At this stage, a
greater percentage of Fab mini‐pools expressed product compared to
the IgG1 transfectants (Figure 1d) and, on average, Fab mini‐pools
expressed significantly higher protein concentrations than their
equivalent IgG1 partner (Figure 1e; p < 0.0001). From the product
concentration measured by Octet®, the 20 highest producing
F IGURE 1 Summary of the cell line development process and the progression of mini‐pools at each stage. The flowchart summarizes the cell
line development process and cell pool selection at each stage (a). The plots (b–f) show data for pools at the 96‐well plate (purple), 24‐well
plate (blue), and 125ml shake flask (red) stages. The recovery of pools posttransfection is shown as the proportion of wells in 96‐well plates that
contained a single colony (mini‐pool) compared to the total number of wells seeded posttransfection (b). The number of mini‐pools
progressed from 96‐well plates to 24‐well plates (up to 96 mini‐pools per cell line) are shown (c). Percentage number of mini‐pools in 24‐well
plates that gave a detectable level of product on the Octet® (d). Product concentration measurements and mean (solid black bar) for each
molecule are shown at the 24‐well stage, as well as, the average across both formats shown in a separate plot (Fab a–c vs. IgG1 a–c) (e).
HPLC (Protein G) titer measurements and mean (solid black bar) for all 20 mini‐pools at the 125ml shake flask stage as well as, the average across
both formats shown in a separate plot (Fab a–c vs. IgG1 a–c) (f). The data were analyzed using a two‐tailed t‐test, where p‐values of <0.05 were
deemed significantly different. Bars highlight the comparisons and associated p‐values are displayed above each plot
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mini‐pools were expanded into 125ml Erlenmeyer shake flasks
(Figure 1a). These mini‐pools were cultured until they reached pre‐
determined culture viability (>90% viability after 3–4 passages)
and then subjected to a 9‐day batch overgrow culture. Post-
harvest product concentration in the culture medium was measured
by HPLC (Protein G; Figure 1f). The IgG1 mini‐pools had significantly
higher product concentration than the top‐20 Fab mini‐pools
(Figure 1f; p = 0.0277).
When comparing between stages of the cell line development
process, at the 24‐well stage on average the Fab mini‐pools ex-
pressed significantly higher protein concentration than the IgG.
However, at the shake flask stage for the top‐20 mini‐pools, the
pattern reversed and the IgG1s had significantly higher average
protein concentration compared to the counterpart Fab mini‐pools
(Figure 1e,f).
Clear differences were observed in the number of mini‐pools
that recover posttransfection between the Fab and IgG1 formats
(also for the average product concentrations for both formats at
different stages of the cell line development process). Taken to-
gether, the recovery data and early stage cell line development
process data suggest that the full‐length IgG1 molecule imposes a
different “burden” on transfected cells but this does not ultimately
impact product concentration in terms of the mass of protein
produced during later shake flask expression.
3.2 | Analysis of IgG and Fab formats reveals
differences between product yield by mass and the
number of molecules produced by cells
Given the molecular size differences, we calculated protein con-
centration on a molar basis as the number of molecules produced for
all the Fab and IgG1 mini‐pools at the 24‐well (Figure 2a) and shake
flask stages (Figure 2b) of cell line development. For the 24‐well plate
data, the number of molecules produced by Fab mini‐pools was
twofold greater than that for IgG1 mini‐pools, a finding that corre-
lates with the product concentration determined by Octet®
(Figure 1e). At the shake flask stage, Fab molecule production was
two times that observed for the “partner” IgG1 mini‐pools (Figure 2b).
This contrasts with the interpretation based on product concentra-
tion where the concentration of IgG1 was greater than the Fab‐
expressing mini‐pools (Figure 1f). The results suggest that although
differences are observed in product concentration (mg/L) throughout
the cell development process, more Fab molecules are consistently
produced by cells at all process stages. Therefore, the data questions
what measurements are appropriate to describe cell productivity and
to compare the productivity of the different formats.
The product concentration is a measure of the total raw mass of
material produced (grams per liter), whereas, the molar analysis or
molecule productivity measures the number of molecules of product
(this can be per cell or volume). Depending on the measurement used,
the product concentration or molar analysis, a different perspective is
obtained from the data in terms of productivity between different
formats. The molar analysis allows discrimination between the dif-
ferences in molecular weight between formats and provides a mea-
sure of the number of molecules a cell can produce. This is perhaps a
better descriptor of the efficiency of cells to fold, assemble and se-
crete molecules of different formats than raw mass per unit volume
and so may have important utility when performing academic studies.
We, therefore, suggest that traditional mass‐based comparisons of
the efficiency by which cells produce different format molecules can
be misleading in terms of establishing whether a particular format is
more or less easy to express than a comparator and a molecular basis
is more revealing in this regard.
3.3 | High‐throughput screening reveals no
predictive indicators of recovery and high‐producing
mini‐pools between molecule formats and cell culture
stages
We also investigated potential predictive indicators of successful
recovery from transfection of the different formats. The efficiency
of transfection and the percentage of wells that gave successful
F IGURE 2 Summary of the molar concentration of all mini‐pools. From the product concentration (Octet® measurement) for all mini‐pools
at the 24‐well stage (Figure 1d), the molar concentrations (a) were calculated considering the molecular weight for the Fab (50 kDa) and IgG1
(150 kDa) and then the total number of molecules for the number of moles was calculated using Avogadro's number (1 mole = 6.022 × 1023
molecules). From the HPLC (Protein G) titer measurements for all 20 mini‐pools at the 125ml shake flask stage, the total number of molecules
for the number of moles in a liter was calculated (b). The mean is reflected in each plot as a solid black bar
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mini‐pool growth were assessed by measuring colony size at the
96‐well plate stage. No correlation was observed between the size of
the mini‐pool at the 96‐well plate stage and the product concentra-
tion at the 24‐well stage and the final performance at the shake flask
stage. The data for the highest expressing mini‐pools at the shake
flask stage was traced back to the 24‐well plate stage (Figure 1a,e,f)
to determine if there was any predictability between the different cell
culture scales, and whether high performing mini‐pools could be
detected earlier in the process as others have published (Davies
et al., 2013; Porter, Dickson, et al., 2010; Porter, Racher, et al., 2010;
Poulain et al., 2019; Rouiller et al., 2016). Examination of the data
revealed that the rank was not preserved between the stages for any
of the mini‐pools (Figure S1), confirming that screening is necessary
at each stage to identify high‐producing mini‐pools of either format.
3.4 | The molecular format and variable region
sequence impact the observed cell pool
characteristics
The top‐12 mini‐pools (based on product concentration) were taken
forward for detailed analysis of cell pool characteristics such as
growth, product concentration, and cell‐specific productivity (qP)
over a 9‐day batch culture (Figure 1a) in shake flasks. The growth
profiles for all mini‐pools were alike, reaching similar maximum viable
cell concentrations (7–9 × 106 cells/ml; Figure S2). In most cases, the
culture viability began to drop after Day 6 of culture, however with a
number of mini‐pools for Fab B and IgG1 B, the culture viability
started to decrease earlier in culture. The fact that this was the case
with both formats with the B variable region specificity, suggests
potential cytotoxic effects arising from the molecular features of this
specificity‐region sequence.
To ascertain whether the extent of protein production had
effects on cell growth, specific growth rate (in the exponential
phase) and doubling time were calculated (Table S1). No significant
difference was observed between the specific growth rate of the
matching pair of molecules of the same variable region specificity
(p = 0.0753–0.6961).
The Fab C mini‐pools showed a negative correlation (R2 = 0.511,
p = 0.009; Figure S3) between specific growth rate and qP, but no
other set of mini‐pools showed a statistically significant correlation
(p = 0.1886–0.5958; Figure S3). The average cell diameter of all top‐
12 mini‐pools for each format showed the same overall trend (de-
crease) across the 9‐day batch culture with no clear differences be-
tween A, B, and C mini‐pools (Figure S4). Taken together, the cell
growth data and cell characteristics examined revealed no defining
features between mini‐pools expressing either a Fab or IgG1 format,
as well as, molecules with a specific variable region.
For all the Fab and IgG1 top‐12 mini‐pools, the cell growth data
and product concentration were used to calculate the qP over the
entire 9‐day batch culture (Figures 3 and S5). Comparing the range in
qP between all 12 mini‐pools for each molecule, the Fab mini‐pools
displayed a narrow range of qP (1.9‐ to 3.8‐fold range; Figures 3
and S5) whereas IgG1 pools had a wider range in qP compared to the
Fab mini‐pools (2.5‐ to 8.8‐fold range; Figures 3 and S5). Values for
qP for the IgG1 mini‐pools were in line with published literature
(Kunert & Reinhart, 2016; LE Fourn et al., 2014; Mason et al., 2012).
The average specific productivity for the top‐12 mini‐pools for the
Fab format was significantly lower than the corresponding IgG1
format (p ≤ 0.0101; Figure 3a). Though the qP of the Fab mini‐pool
were lower than the corresponding IgG1, the number of molecules
produced per cell day (molecules/cell/day) were significantly greater
in Fab A and Fab C mini‐pools compared to IgG1 A and IgG1 C mini‐
pools, respectively (p ≤ 0.0101; Figure 3b).
Variable region sequence appeared to have a stronger influence
on qP than the molecular format but the ranking of variable domain
sequences was not preserved between Fab and IgG formats. For the
Fab mini‐pools, the average qP ranking was C > A > B whereas for the
IgG1 mini‐pools the ranking was C > B > A. The IgG1 C and Fab C
mini‐pools consistently had the highest qP and number of molecules
produced (Figure 3). As a result, they were subjected to further study
to investigate molecular processes that might determine the effi-
ciency of recombinant protein production in these industry‐grade
high‐producing mini‐pools.
3.5 | Assessment of secreted and intracellular IgG
and Fab protein
Fab C and IgG1 C mini‐pools were sampled for secreted (Figures 4
and 5) and intracellular protein (Figure S6) on Day 6 of culture to
assess the status of the protein and assembly of the different format
molecules. A subset of mini‐pools with a range of qP across those
available (indicated as relative to each other low, mid and high) was
selected for protein analysis (8 out of 12 mini‐pools; Figure S5).
Secreted HC (detected with anti‐human CH1 domain antibody;
Figure 4a) and LC (detected with anti‐human kappa antibody;
Figure 4b) were examined under reducing Western blot conditions
for all Fab C and IgG1 C mini‐pools. Between the top‐12 mini‐pools,
there were no apparent differences in the amounts of each poly-
peptide chain (Figure 4c,d) and there was no evidence of protein
degradation. As expected, more HC and LC were detectable in cul-
ture medium samples than in cell lysates (Figure S6). There was no
evidence of material being retained within the cell and no obvious
difference was observed in protein quality and integrity. Thus, there
was no evidence that lower cell productivity was associated with the
production of aberrant protein species.
To further assess the ability of cells to correctly fold and as-
semble the target molecules, and to examine if the efficiency of this
process was affected by the format, the protein samples were
analyzed under nonreducing Western blot conditions (Figure 5). The
Fab C protein was detected predominantly at its expected molecular
weight (~50 kDa) with both anti‐HC (Figure 5a) and anti‐LC
(Figure 5b) antibodies with no difference in the protein species
present. As expected for the IgG1 C mini‐pools, multiple HC and
LC intermediates were detected compared to the Fab mini‐pools
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(Figure 5). The larger number of IgG1 intermediates is likely due to
the increased posttranslational processing of this molecule with
HCs of greater size and complexity. Complex banding patterns have
generally been attributed substantially to incomplete intermolecular
disulfide bond formation (Peters et al., 2012). Generally, the type
and abundance of intermediates detected in the IgG1 samples were
similar between mini‐pools regardless of the qP ranking with
the exception of the bottom two ranking IgG1 mini‐pools. The
second‐lowest ranked IgG1 C mini‐pool (rank 11) contained no LC
dimer (highlighted by an asterisk, Figure 5b). In addition, the IgG1 C
mini‐pool at rank 12 showed the presence of an unknown inter-
mediate containing both HC and LC in culture medium samples
(highlighted by an arrow, Figure 5). This IgG1 C intermediate was not
detected within cell lysates (data not shown). The data suggests the
highest producing mini‐pools for both formats generally process the
proteins similarly.
3.6 | The amount of messenger RNA correlates to
Fab production whereas posttranscriptional processes
may limit IgG1 production
As the protein analyses revealed little difference between mini‐pools
for each format, both formats were analyzed for genomic DNA
(gDNA) copy number and messenger RNA (mRNA) transcript number.
The aim of this was to investigate whether gDNA and mRNA copies
F IGURE 3 Cell productivity of IgG1 and Fab formats. The cell‐specific productivity (qP, pg/cell/day) is shown for the top‐12 full‐length IgG1
and Fab mini‐pools (a). IgG1 and Fab concentrations were measured using an HPLC (mg/L) from supernatant samples taken on Days 3, 6, and
9 of culture. The cell‐specific productivity (qP, pg/cell/day) was calculated using the concentrations and corresponding integral of viable cell
concentration (×106 cells/ml/day) for the same days of culture. From the qP calculation (per/cell/day), the molar ratio was calculated considering
the molecular weight for the IgG1 (150 kDa) and Fab (50 kDa) (b). From the molar ratio per cell per day, the number of molecules produced per
cell per day was calculated using Avogadro's number (1 mole = 6.022 × 1023 molecules). The mean is reflected in each plot as a horizontal solid
black bar and the range (minimum and maximum values) is highlighted with vertical black bars. The data were analyzed by two‐way ANOVA,
where p‐values of <0.05 were deemed significantly different. Bars highlight the comparisons and associated p‐values are displayed above
each plot
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might define protein production for IgG1 and Fab formats and
identify potential bottlenecks along the production pathway.
Genomic DNA was extracted from frozen pellets collected on
day 6 of culture and the copy number of light and HC per cell was
determined for Fab C and the IgG1 C samples (Figure S7) on a subset
of pools (designated low, mid, and high qP, 6 out of 12 mini‐pools;
Figure S5). We note that when transfecting either the full‐length
IgG1 or Fab constructs into cells with the same amount of linearized
plasmid DNA was used, and as a result, a different number of copies
of IgG1 and Fab being transfected. However, the nature of trans-
fection means we cannot determine how many copies of a given
plasmid are transfected into any of the recovering cells and thus it is
not possible to comment on any relationship between transfected
copy numbers and mini‐pool recovery or cell productivity. What we
can deduce is the number of genomic integrated copies of each gene
in the pools for the Fab C and IgG C pair which shows that between 2
and 10 HC and LC copies (y‐axis; Figure S7) were integrated into five
out of six of the Fab and IgG1 mini‐pools evaluated and thus these
were broadly equivalent (Figure S7). Further, for the Fab C and IgG C
mini‐pools, there was no correlation between the LC and HC gDNA
copies per cell and the number of molecules/cell/day (Figure S7).
Other studies have also reported that cell productivity does not
correlate to gene copy numbers (Balasubramanian et al., 2018;
Barnes & Dickson, 2006; Lattenmayer et al., 2007; Reisinger
et al., 2008; Sergeeva et al., 2020). The lack of correlation between
gDNA copy number and the number of molecules/cell/day is most
likely to be a result of the random integration of the DNA within the
genome of the cell. As the DNA is not targeted to a specific site
within the genome, integration at random locations can cause dif-
ferences in gene expression due to site‐specific differences in tran-
scription rate (Barnes et al., 2003, 2004; Wilson et al., 1990).
Next, the mRNA copy number for the same mini‐pools were
examined. The mRNA copies of the LC and HC were also de-
termined from pellets collected on Day 6, for Fab C and IgG1 C
samples (Figures 6 and S8). Initially, we checked if the gDNA copies
correlated with the mRNA copies. For the Fab C samples
(Figure S8a,b), there was no correlation between the copies of
gDNA and copies of LC or HC mRNA copies (p = 0.5457 and 0.2277,
respectively). The lack of correlation between gDNA and mRNA
copy numbers again suggests that random integration is a major
F IGURE 4 Analysis of secreted heavy and light chains in culture medium samples for IgG1 C and Fab C cell lines. Culture medium was
harvested on Day 6 of culture (exponential growth phase) for secreted protein analysis. Samples were analyzed by Western blot analysis under
reducing conditions (with 1.8% (v/v) β‐mercaptoethanol). Western blot images and quantitation are shown for heavy chain (a, c) and light chain
(b, d) detection for 8 out of 12 mini‐pools selected for each cell line with a range in qP. The mini‐pools selected were of high qP (ranks 1, 2, and
3), mid qP (ranks 5, 7, and 9) and low qP (ranks 11 and 12). Data are shown in rank order (decreasing qP). A commercial IgG was used as a
positive control (IgG control). Data shown are representative of three replicates and error bars show the mean ± standard deviation (n = 3)
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factor in determining the mRNA expression. Similarly, for the par-
allel IgG1 C samples, there was no clear correlation between the
gDNA copies of LC or HC and their corresponding mRNA copy
number (p = 0.0775 and 0.0689, respectively; Figure S8d,e). The
ratio of mRNA HC to LC was also examined in relationship to the
molecules/cell/day observed and were found to lie within a very
narrow range of 1.96–3.84 (Figure S8c,f), and there was no statis-
tical correlation between ratio and number of molecules produced
(p = 0.1320 and 0.2133, respectively).
The mRNA data were further analyzed to determine if the LC
and HC transcript numbers correlated (Figure 6a,b). For both the
Fab C and IgG1 C, there was a strong correlation between LC and
HC mRNA copies (R2 values of 0.780 and 0.761, respectively).
This may have been expected since LC and HC are encoded on the
same vector. For the Fab C mini‐pools, the number of molecules/
cell/day positively correlated with LC and HC and dihydrofolate
reductase (DHFR) mRNA (Figure 6c–e). On the other hand, there
was no correlation for IgG1 between the number of molecules/
cell/day and LC, HC, or DHFR mRNA (Figure 6f–h). This infers
that, at least in the panel of pools investigated here, mRNA
amounts are a limiting factor for Fab production in CHO cells but
not for the IgG1 format. This suggests that for the Fab molecule
LC and HC mRNA are not saturated and thus enhancing mRNA
amounts for the Fab format could further enhance yields. This
could be achieved by using stronger promoters or site‐directed
integration to highly transcriptionally active sites in the genome.
Bottlenecks at the mRNA level have previously been reported for
other molecules (Godfrey et al., 2017; Jiang et al., 2006; Lee
et al., 2009; Mason et al., 2012; Mead et al., 2009; Pekle
et al., 2019). For IgG1, posttranscriptional processes must limit
product yields as reported in the literature for other recombinant
targets (Chusainow et al., 2009; Godfrey et al., 2017; Hussain
et al., 2017; Ley et al., 2015; Mason et al., 2012; Mead
et al., 2009, 2015; Mohan et al., 2008; O'callaghan et al., 2010;
Reisinger et al., 2008).
Finally, we performed a comparison on variable regions A, B, and
C in both Fab and IgG formats of mRNA versus molecular pro-
ductivity (Figure S9). Whilst it is difficult to make broad conclusions
when studying three variable regions only, some interesting ob-
servations are apparent. First, LC and HC mRNA to molecules per
cell/day correlations (Figure S9a,b,d,e) are very different to those of
DHFR mRNA (Figure S9c,f). This is perhaps not unsurprising, since
mini‐pools were selected for molecule production, not differential
DHFR activity. Second, variable region B (blue triangles) sit discretely
away from variable regions A (red squares) and C (green circles) in both
Fab and IgG formats when correlating with both LC and HC mRNA
(Figure S9). Whilst we do not know the drivers behind these differ-
ences, it does underline the central influence of variable regions on
molecular and cellular biology aspects of antibody cell line production
processes.
F IGURE 5 Analysis of secreted heavy and light chains in culture medium samples under nonreducing conditions for IgG1 C and Fab C.
Culture medium was harvested on Day 6 of culture (exponential growth phase) for secreted protein analysis. Samples were analyzed by Western
blot analysis under nonreducing conditions. Images are shown for the heavy chain (a) and light chain (b) detection for Fab C (top panel) and
IgG1 C (bottom panel). Data are shown for 8 out of 12 mini‐pools selected for each cell line with a range in qP. The mini‐pools selected
were of high qP (ranks 1, 2, and 3), mid qP (ranks 5, 7, and 9), and low qP (ranks 11 and 12). Data are shown in rank order (decreasing qP).
A commercial IgG was used as a positive control (IgG control). Intermediates were predicted based on molecular weight and differences in
intermediates between IgG1 mini‐pools are highlighted (arrow and asterisk). Data shown are representative of three replicates
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4 | SUMMARY
This study illustrates the different influences of different variable
regions and antibody formats on a CHO cell line construction and
molecule production process. During the cell line construction
process, the full‐length antibody format resulted in fewer mini‐pools
recovered posttransfection compared to the corresponding Fab
molecule. However, later in the cell line construction process, the
antibody‐producing cell pools achieved higher protein yields (mg/L)
and specific productivity compared to the corresponding Fab pools.
Conversely, the number of molecules produced per cell was greater
for the Fab molecule compared to the IgG suggesting that the cells
are more efficient at making Fab molecules than the larger full‐
length IgG. Further, we have established the potential for significant
Fab expression (specific productivity of up to 11 pg/cell/day) in
CHO cells with no evidence of aberrant protein species. Molecular
analysis of the cell pools (genomic DNA, messenger RNA, as well as,
intracellular and secreted protein analysis) showed that production
of each format was not limited to a single locus. The Fab format was
limited in the amount of mRNA and/or posttranscriptional pro-
cesses, whereas, posttranslational processes were limiting for the
IgG format. Finally, antibody variable region sequences were shown
to influence the cell line construction process, including the
recovery of cell pools after transfection and the cell‐specific pro-
ductivity for each format.
ACKNOWLEDGMENTS
This study was funded by support from a BBSRC LINK grant
awarded to AJD (BB/R002096/1, University of Manchester) and
CMS (BB/R001731/1, University of Kent) and funding supplied by
UCB Pharma.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
AUTHOR CONTRIBUTIONS
Alan J. Dickson, Christopher M. Smales, Paul E. Stephens, and Bernie
Sweeney conceived the study. Alan J. Dickson, Christopher
M. Smales, Mark Ellis, Matthew Hinchliffe, David P. Humphreys, Paul
E. Stephens, Bernie Sweeney, and JamesWhite supervised the study.
Hirra Hussain, Tulshi Patel, Angelica M. S. Ozanne, and Davide Vito
designed and completed the experiments. Hirra Hussain and Angelica
M. S. Ozanne wrote the manuscript with the support of Alan J.
Dickson, Christopher M. Smales, Mark Ellis, and David P. Humphreys.
All authors reviewed and approved the manuscript before
submission.
F IGURE 6 Analysis of heavy chain, light chain, and DHFR mRNA for IgG1 C and Fab C cell lines. Cell pellets were harvested on Day 6 of
culture for mRNA analysis by RT‐qPCR. Light chain, heavy chain, and DHFR mRNA copies were quantified for 6 out of 12 mini‐pools for each
cell line with a range in qP. The mini‐pools selected were of high qP (ranks 1 and 2), mid qP (ranks 5 and 9), and low qP (ranks 11 and 12).
The light chain and heavy chain mRNA copies were examined for Fab C (a) and IgG1 C (b) with the molecules/cell/day for each mini‐pool
detailed next to the corresponding data point. The mRNA copies of light chain (c, f), heavy chain (d, g), and DHFR (e, h) were also plotted against
the molecules/cell/day for Fab C (c, d, and e, respectively) and for IgG1 C (f, g, and h, respectively)
HUSSAIN ET AL. | 11
DATA AVAILABILITY STATEMENT
The authors confirm that the data supporting the findings of this




Alan J. Dickson http://orcid.org/0000-0001-9490-645X
Christopher M. Smales https://orcid.org/0000-0002-2762-4724
REFERENCES
Akram, M. S., Pery, N., Butler, L., Shafiq, M. I., Batool, N., Rehman, M. F. U.,
Grahame‐Dunn, L. G., & Yetisen, A. K. (2021). Challenges for
biosimilars: Focus on rheumatoid arthritis. Critical Reviews in
Biotechnology, 41, 121–153.
Balasubramanian, S., Peery, R. B., Minshull, J., Lee, M., White, R.,
Kelly, R. M., & Barnard, G. C. (2018). Generation of high expressing
Chinese hamster ovary cell pools using the Leap‐In transposon
system. Biotechnology Journal, 13, e1700748.
Barnes, L. M., Bentley, C. M., & Dickson, A. J. (2003). Stability of protein
production from recombinant mammalian cells. Biotechnology and
Bioengineering, 81, 631–639.
Barnes, L. M., Bentley, C. M., & Dickson, A. J. (2004). Molecular
definition of predictive indicators of stable protein expression in
recombinant NSO myeloma cells. Biotechnology and Bioengineering,
85, 115–121.
Barnes, L. M., & Dickson, A. J. (2006). Mammalian cell factories for
efficient and stable protein expression. Current Opinion in
Biotechnology, 17, 381–386.
Camper, N., Byrne, T., Burden, R. E., Lowry, J., Gray, B., Johnston, J. A.,
Migaud, M. E., Olwill, S. A., Buick, R. J., & Scott, C. J. (2011). Stable
expression and purification of a functional processed Fab' fragment
from a single nascent polypeptide in CHO cells expressing the
mCAT‐1 retroviral receptor. Journal of Immunological Methods, 372,
30–41.
Chusainow, J., Yang, Y. S., Yeo, Y. H. M., Toh, P. C., Asvadi, P.,
Wong, N. S. C., & Yap, M. G. S. (2009). A study of monoclonal
antibody‐producing CHO cell lines: What makes a stable
high producer? Biotechnology and Bioengineering, 102,
1182–1196.
Dariushnejad, H., Farajnia, S., Zarghami, N., Aria, M., & Tanomand, A.
(2019). Effect of DnaK/DnaJ/GrpE and DsbC chaperons on
periplasmic expression of Fab antibody by E. coli SEC pathway.
International Journal of Peptide Research and Therapeutics, 25,
67–74.
Dave, E., Adams, R., Zaccheo, O., Carrington, B., Compson, J. E.,
Dugdale, S., Airey, M., Malcolm, S., Hailu, H., Wild, G., Turner, A.,
Heads, J., Sarkar, K., Ventom, A., Marshall, D., Jairaj, M.,
Kopotsha, T., Christodoulou, L., Zamacona, M., … Humphreys, D. P.
(2016). Fab‐dsFv: A bispecific antibody format with extended serum
half‐life through albumin binding. mAbs, 8, 1319–1335.
Davies, S. L., Lovelady, C. S., Grainger, R. K., Racher, A. J., Young, R. J., &
James, D. C. (2013). Functional heterogeneity and heritability in
CHO cell populations. Biotechnology and Bioengineering, 110,
260–274.
Ellis, M., Patel, P., Edon, M., Ramage, W., Dickinson, R., &
Humphreys, D. P. (2017). Development of a high yielding E. coli
periplasmic expression system for the production of humanized Fab'
fragments. Biotechnology Progress, 33, 212–220.
Farajnia, S., Ghorbanzadeh, V., & Dariushnejad, H. (2020). Effect of
molecular chaperone on the soluble expression of recombinant Fab
Fragment in E. coli. International Journal of Peptide Research and
Therapeutics, 26, 251–258.
Feige, M. J., Hendershot, L. M., & Buchner, J. (2010). How antibodies fold.
Trends in Biochemical Sciences, 35(4), 189–198.
Gadkar, K., Pastuskovas, C. V., Le Couter, J. E., Elliott, J. M., Zhang, J. H.,
Lee, C. V., Sanowar, S., Fuh, G., Kim, H. S., Lombana, T. N., Spiess, C.,
Nakamura, M., Hass, P., Shatz, W., Meng, Y. G., & Scheer, J. M. (2015).
Design and pharmacokinetic characterization of novel antibody
formats for ocular therapeutics. Investigative Ophthalmology & Visual
Science, 56, 5390–5400.
Godfrey, C. L., Mead, E. J., Daramola, O., Dunn, S., Hatton, D., Field, R.,
Pettman, G., & Smales, C. M. (2017). Polysome profiling of mAb
producing CHO cell lines links translational control of cell
proliferation and recombinant mRNA loading onto ribosomes
with global and recombinant protein synthesis. Biotechnology
Journal, 12.
Gundinger, T., & Spadiut, O. (2020). pH conditioning is a crucial step in
primary recovery – A case study for a recombinant Fab from E. coli.
Protein Expression and Purification, 165, 105504.
Gupta, S. K., & Shukla, P. (2017). Microbial platform technology for
recombinant antibody fragment production: A review. Critical
Reviews in Microbiology, 43, 31–42.
Huang, Y. M., Hu, W., Rustandi, E., Chang, K., Yusuf‐Makagiansar, H., &
Ryll, T. (2010). Maximizing productivity of CHO cell‐based fed‐
batch culture using chemically defined media conditions and
typical manufacturing equipment. Biotechnology Progress, 26,
1400–1410.
Huber, R., Deisenhofer, J., Colman, P. M., Matsushima, M., & Palm, W.
(1976). Crystallographic structure studies of an IgG molecule and an
Fc fragment. Nature, 264, 415–420.
Humphreys, D. P., Heywood, S. P., Henry, A., Ait‐Lhadj, L., Antoniw, P.,
Palframan, R., Greenslade, K. J., Carrington, B., Reeks, D. G.,
Bowering, L. C., West, S., & Brand, H. A. (2007). Alternative antibody
Fab' fragment PEGylation strategies: Combination of strong
reducing agents, disruption of the interchain disulphide bond and
disulphide engineering. Protein Engineering, Design & Selection, 20,
227–234.
Humphreys, D. P., Weir, N., Lawson, A., Mountain, A., & Lund, P. A. (1996).
Co‐expression of human protein disulphide isomerase (PDI) can
increase the yield of an antibody Fab' fragment expressed in
Escherichia coli. FEBS Letters, 380, 194–197.
Hussain, H., Fisher, D. I., Abbott, W. M., Roth, R. G., & Dickson, A. J.
(2017). Use of a protein engineering strategy to overcome
limitations in the production of “Difficult to Express”
recombinant proteins. Biotechnology and Bioengineering, 114,
2348–2359.
Hussain, H., Fisher, D. I., Roth, R. G., Abbott, W. M., Carballo‐Amador,
M. A., Warwicker, J., & Dickson, A. J. (2018). A protein chimera
strategy supports production of a model “difficult‐to‐express”
recombinant target. FEBS Letters, 592, 2499–2511.
Jiang, Z., Huang, Y., & Sharfstein, S. T. (2006). Regulation of
recombinant monoclonal antibody production in Chinese
hamster ovary cells: A comparative study of gene copy number,
mRNA level, and protein expression. Biotechnology Progress, 22,
313–318.
Joosten, V., Lokman, C., Van Den Hondel, C. A., & Punt, P. J. (2003). The
production of antibody fragments and antibody fusion proteins by
yeasts and filamentous fungi. Microbial Cell Factories, 2, 1.
Kumar, D., Batra, J., Komives, C., & Rathore, A. S. (2019). QbD based
media development for the production of Fab fragments in E. coli.
Bioengineering, 6, 29.
Kunert, R., & Reinhart, D. (2016). Advances in recombinant antibody
manufacturing. Applied Microbiology and Biotechnology, 100,
3451–3461.
12 | HUSSAIN ET AL.
LE Fourn, V., Girod, P. A., Buceta, M., Regamey, A., & Mermod, N. (2014).
CHO cell engineering to prevent polypeptide aggregation and
improve therapeutic protein secretion. Metabolic Engineering, 21,
91–102.
Lattenmayer, C., Trummer, E., Schriebl, K., Vorauer‐Uhl, K., Mueller, D.,
Katinger, H., & Kunert, R. (2007). Characterisation of recombinant
CHO cell lines by investigation of protein productivities and genetic
parameters. Journal of Biotechnology, 128, 716–725.
Lebozec, K., Jandrot‐Perrus, M., Avenard, G., Favre‐Bulle, O., & Billiald, P.
(2018). Quality and cost assessment of a recombinant antibody
fragment produced from mammalian, yeast and prokaryotic host
cells: A case study prior to pharmaceutical development. New
Biotechnology, 44, 31–40.
Lee, C. J., Seth, G., Tsukuda, J., & Hamilton, R. W. (2009). A clone
screening method using mRNA levels to determine specific
productivity and product quality for monoclonal antibodies.
Biotechnology and Bioengineering, 102, 1107–1118.
Ley, D., Seresht, A. K., Engmark, M., Magdenoska, O., Nielsen, K. F.,
Kildegaard, H. F., & Andersen, M. R. (2015). Multi‐omic profiling ‐of
EPO‐producing Chinese hamster ovary cell panel reveals metabolic
adaptation to heterologous protein production. Biotechnology and
Bioengineering, 112, 2373–2387.
Mason, M., Sweeney, B., Cain, K., Stephens, P., & Sharfstein, S. T.
(2012). Identifying bottlenecks in transient and stable production
of recombinant monoclonal‐antibody sequence variants in
Chinese hamster ovary cells. Biotechnology Progress, 28,
846–855.
Mead, E. J., Chiverton, L. M., Smales, C. M., & Von Der Haar, T. (2009).
Identification of the limitations on recombinant gene expression in
CHO cell lines with varying luciferase production rates.
Biotechnology and Bioengineering, 102, 1593–1602.
Mead, E. J., Masterton, R. J., Feary, M., Obrezanova, O., Zhang, L.,
Young, R., & Smales, C. M. (2015). Biological insights into the
expression of translation initiation factors from recombinant
CHOK1SV cell lines and their relationship to enhanced
productivity. Biochemical Journal, 472, 261–273.
Mizote, Y., Masumi‐Koizumi, K., Katsuda, T., & Yamaji, H. (2020).
Production of an antibody Fab fragment using 2A peptide in insect
cells. Journal of Bioscience and Bioengineering, 130, 205–211.
Mohan, C., Kim, Y.‐G., & Lee, G. M. (2008). Assessment of cell engineering
strategies for improved therapeutic protein production in CHO cells.
Biotechnology Journal, 3, 624–630.
Nakamura, H., Anraku, M., Oda‐Ueda, N., Ueda, T., & Ohkuri, T. (2020). C‐
terminal cysteine PEGylation of adalimumab fab with an engineered
interchain SS bond. Biological and Pharmaceutical Bulletin, 43,
418–423.
O'callaghan, P. M., Mcleod, J., Pybus, L. P., Lovelady, C. S., Wilkinson, S. J.,
Racher, A. J., Porter, A., & James, D. C. (2010). Cell line‐specific
control of recombinant monoclonal antibody production by CHO
cells. Biotechnology and Bioengineering, 106, 106–151.
O'flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I.,
Quigley, A., Xie, Y., & Butler, M. (2020). Mammalian cell culture
for production of recombinant proteins: A review of the critical
steps in their biomanufacturing. Biotechnology Advances, 43,
107552.
Pekle, E., Smith, A., Rosignoli, G., Sellick, C., Smales, C. M., & Pearce, C.
(2019). Application of imaging flow cytometry for the
characterization of intracellular attributes in Chinese hamster
ovary cell lines at the single‐cell level. Biotechnology Journal, 14,
e1800675.
Peters, S. J., Smales, C. M., Henry, A. J., Stephens, P. E., West, S., &
Humphreys, D. P. (2012). Engineering an improved IgG4 molecule
with reduced disulfide bond heterogeneity and increased Fab
domain thermal stability. Journal of Biological Chemistry, 287,
24525–24533.
Porter, A. J., Dickson, A. J., & Racher, A. J. (2010). Strategies for
selecting recombinant CHO cell lines for cGMP manufacturing:
Realizing the potential in bioreactors. Biotechnology Progress, 26,
1446–1454.
Porter, A. J., Racher, A. J., Preziosi, R., & Dickson, A. J. (2010). Strategies
for selecting recombinant CHO cell lines for cGMP manufacturing:
Improving the efficiency of cell line generation. Biotechnology
Progress, 26, 1455–1464.
Poulain, A., Mullick, A., Massie, B., & Durocher, Y. (2019). Reducing
recombinant protein expression during CHO pool selection
enhances frequency of high‐producing cells. Journal of
Biotechnology, 296, 32–41.
Reisinger, H., Steinfellner, W., Stern, B., Katinger, H., & Kunert, R. (2008).
The absence of effect of gene copy number and mRNA level on the
amount of mAb secretion from mammalian cells. Applied
Microbiology and Biotechnology, 81, 701–710.
Rodríguez‐Carmona, E., Cano‐Garrido, O., Dragosits, M., Maurer, M.,
Mader, A., Kunert, R., Mattanovich, D., Villaverde, A., & Vázquez, F.
(2012). Recombinant Fab expression and secretion in Escherichia coli
continuous culture at medium cell densities: Influence of
temperature. Process Biochemistry, 47, 446–452.
Rouiller, Y., Bielser, J. M., Brühlmann, D., Jordan, M., Broly, H., &
Stettler, M. (2016). Screening and assessment of performance and
molecule quality attributes of industrial cell lines across different
fed‐batch systems. Biotechnology Progress, 32, 160–170.
Samuelsson, A., Yari, F., Hinkula, J., Ersoy, O., Norrby, E., & Persson, M. A.
(1996). Human antibodies from phage libraries: Neutralizing activity
against human immunodeficiency virus type 1 equally improved
after expression as Fab and IgG in mammalian cells. European Journal
of Immunology, 26, 3029–3034.
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020). Evolution of
Escherichia coli expression system in producing antibody recombinant
fragments. International Journal of Molecular Sciences, 21.
Schatz, S. M., Kerschbaumer, R. J., Gerstenbauer, G., Kral, M., Dorner, F., &
Scheiflinger, F. (2003). Higher expression of Fab antibody fragments
in a CHO cell line at reduced temperature. Biotechnology and
Bioengineering, 84, 433–438.
Sergeeva, D., Lee, G. M., Nielsen, L. K., & Grav, L. M. (2020). Multicopy
targeted integration for accelerated development of high‐
producing Chinese hamster ovary cells. ACS Synthetic Biology 9,
2546–2561.
Shatz, W., Hass, P. E., Peer, N., Paluch, M. T., Blanchette, C., Han, G. H.,
Sandoval, W., Morando, A., Loyet, K. M., Bantseev, V., Booler, H.,
Crowell, S., Kamath, A., Scheer, J. M., & Kelley, R. F. (2019).
Identification and characterization of an octameric PEG‐protein
conjugate system for intravitreal long‐acting delivery to the back of
the eye. PLOS One, 14, 20.
Spiess, C., Zhai, Q., & Carter, P. J. (2015). Alternative molecular formats
and therapeutic applications for bispecific antibodies. Molecular
Immunology, 67, 95–106.
Takagi, Y., Kikuchi, T., Wada, R., & Omasa, T. (2017). The enhancement of
antibody concentration and achievement of high cell density CHO
cell cultivation by adding nucleoside. Cytotechnology, 69, 511–521.
Tang, Q., Onitsuka, M., Tabata, A., Tomoyasu, T., & Nagamune, H. (2018).
Construction of anti‐HER2 recombinants as targeting modules for a
drug‐delivery system against HER2‐positive cells. Anticancer
Research, 38, 4319–4325.
Vazquez‐Lombardi, R., Nevoltris, D., Luthra, A., Schofield, P.,
Zimmermann, C., & Christ, D. (2018). Transient expression of human
antibodies in mammalian cells. Nature Protocols, 13, 99–117.
Walsh, G. (2018). Biopharmaceutical benchmarks 2018. Nature
Biotechnology, 36, 1136–1145.
Wilson, C., Bellen, H. J., & Gehring, W. J. (1990). Position effects on
eukaryotic gene expression. Annual Review of Cell Biology, 6,
679–714.
HUSSAIN ET AL. | 13
Yusakul, G., Sakamoto, S., Tanaka, H., & Morimoto, S. (2018).
Improvement of heavy and light chain assembly by
modification of heavy chain constant region 1 (CH1):
Application for the construction of an anti‐paclitaxel fragment
antigen‐binding (Fab) antibody. Journal of Biotechnology, 288,
41–47.
SUPPORTING INFORMATION
Additional supporting information may be found in the online version
of the article at the publisher’s website.
How to cite this article: Hussain, H., Patel, T., Ozanne, A. M.
S., Vito, D., Ellis, M., Hinchliffe, M., Humphreys, D. P.,
Stephens, P. E., Sweeney, B., White, J., Dickson, A. J., &
Smales, C. M. (2021). A comparative analysis of recombinant
Fab and full‐length antibody production in Chinese hamster
ovary cells. Biotechnology and Bioengineering, 1–14.
https://doi.org/10.1002/bit.27944
14 | HUSSAIN ET AL.
